Table 3. The prevalence of helminth infection at each routine annual visit, by childhood treatment group.
| Age | |||||
| Helminth | Childhood Treatment | 2 years (n = 1428)1 | 3 years (n = 1429)1 | 4 years (n = 1366)1 | 5 years (n = 1319)1 |
| Trichuris trichiura | Placebo | 10 (1.4%) | 32 (4.4%) | 40 (5.8%) | 39 (5.8%) |
| Albendazole | 16 (2.3%) | 31 (4.4%) | 35 (5.2%) | 34 (5.3%) | |
| Ascaris lumbricoides | Placebo | 14 (1.9%) | 19 (2.6%) | 11 (1.6%) | 11 (1.6%) |
| Albendazole | 7 (1.0%) | 6 (0.9%) | 6 (0.9%) | 3 (0.5%) | |
| Schistosoma mansoni | Placebo | 3 (0.4%) | 5 (0.7%) | 9 (1.3%) | 20 (3.0%) |
| Albendazole | 6 (0.9%) | 7 (1.0%) | 10 (1.5%) | 10 (1.6%) | |
| Hookworm | Placebo | 5 (0.7%) | 7 (1.0%) | 10 (1.4%) | 2 (0.3%) |
| Albendazole | 2 (0.3%) | 1 (0.1%) | 5 (0.7%) | 3 (0.5%) | |
| Hymenolepis nana | Placebo | 3 (0.4%) | 7 (1.0%) | 10 (1.5%) | 7 (1.0%) |
| Albendazole | 3 (0.4%) | 7 (1.0%) | 7 (1.0%) | 6 (1.0%) | |
| Mansonella perstans | Placebo | 2 (0.3%) | 2 (0.3%) | 2 (0.3%) | 1 (0.1%) |
| Albendazole | 1 (0.1%) | 2 (0.3%) | 3 (0.4%) | 2 (0.3%) | |
| Trichostrongylus | Placebo | 1 (0.1%) | 1 (0.1%) | 1 (0.1%) | 0 (0%) |
| Albendazole | 2 (0.3%) | 0 (0%) | 0 (0%) | 0 (0%) | |
1
For each annual visit, denominators are slightly lower than in Web Table 3 due to excluding children who were first randomised at that annual visit.